

UCLPartners board

Tuesday 19 January 2016, 16.00-18.00

UCL Partners Meeting Room 1

3rd Floor, 170 Tottenham Court Road

Present: Ajay Kakkar (Chair)
 John Bacon
 Elizabeth Chidgey
 Dominic Dodd
 Stephen Field
 David Fish
 Dennis Gillings (by telephone)
 Helen Jameson
 David Lomas
 Martin McKee
 Richard Murley
 Andrew Nebel
 Clifford Prior

Apologies: Michael Arthur
 Tessa Blackstone
 Simon Gaskell

In attendance: Amanda Coyle (GLA)
 Charlie Davie
 Julian Nettel (Interim CEO, Moorfields)
 Diana Rawstron
 Hilary Ross
 Peter Steer (CEO GOSH)
 Steven Thornton (Vice Principal (Health), QMUL)

Declarations

There were no additional declarations of interest.

Minutes

The minutes of the meeting held on 20 October 2015 were approved and signed.

3. Matters arising

Minute 7 - The update on the RNOH proposal will be brought to the March board meeting.

4. Academic Health Science Campus

Julian Nettel presented a paper giving an update on Moorfield's designation as a national vanguard site and its potential future as part of a new health science campus at St. Pancras. If all went to plan, the scheme would be completed in about five years.

Amanda Coyle said that the proposal had the support of the Mayor and the GLA.

The Board welcomed this exciting proposal and confirmed their support for it.

5. North Thames Genomics Medicine Centre (NTGMC)

Peter Steer presented a paper giving an update on the NTGMC and the reconfiguration of genetics laboratories.

The NTGMC is the largest contributor nationally having contributed 22% of all Rare Disease genomes to date. It is in the process of taking on the Royal National Orthopaedic Hospital as a Local Delivery Partner (LDP) to increase cancer recruitment by recruiting patients with sarcoma. The cancer programme is still subject to change but plans are being made to take on more LDPs later this year to expand recruitment to cancer across the network.

The issue of the final specification for reconfiguration of the genomics laboratories has been delayed. Meanwhile progress had been made in comparing activity information and looking at how to rationalise duplications in service.

David Fish commented that it was understood by NHSE that the project was underfunded but it was essential to go ahead.

6. New models of care

Hilary Ross presented a paper setting out a high-level overview of health and social care system transformation across UCL Partners.

In addition to the six designated vanguards and four ACOs, UCL Partners is working on a number of local strategies including Transforming Services Together across three boroughs in north east London, the recent health economy review in north central London, the Success Regime in Mid and South Essex and Your Care Your Future in West Herts.

The key message is pace and UCL Partners can contribute by challenging timescales and supporting all Partners understand it is possible to move more quickly.

It was suggested it would be helpful for UCLP to build in a legal analysis highlighting points which were genuine legal obstacles to change and those which were not.

7. Risk and Audit Committee

Mr Murley reported that the Committee had reviewed how UCLP worked, the insurances, financial controls, staff handbook, EU data protection and risks.

The Board authorised the Committee to approve the year end accounts.

8. UCL Partners Performance Report

The Board received the Performance Report to December 2015 covering strategic risks, sustainability, innovation, capability and the AHSC.

There was no change to the strategic risks and mitigations had been identified.

Business cash remains strong.

UCLP is the global leader for Quintiles recruitment and has secured funding of £2.1m for SBRI Healthcare and £7.5m for the NHS Innovation Accelerator (NIA) fellowship programme.

The Patient Safety Programme continues to make good progress with both the AKI and sepsis workstreams gaining momentum.

There is progress at all the AMCs and recruitment for the Director of the Joint Cardiovascular Institute will start in January.

9. UCL Partners branding

David Fish presented a paper clarifying the use of UCL Partners' brand.

UCL Partners had grown considerably over recent years and the use of the brand was complex as it applied to the company itself, the collection of partners and a geographic area.

The Board agreed the principles put forward in the paper as the basis for a more detailed paper for approval at the March Board meeting.

10. UCL Partners Draft Strategic Priorities 2016/17

The Board approved the proposed strategic themes and underlying priorities which will form the basis of the 2016/17 business plan.

The business plan and budget will be considered at the March Board meeting.

11. Revised dates of future meetings

Tuesday 22 March 2016

Monday 20 June 2016

Monday 19 September 2016

CHAIR